Literature DB >> 11282701

Effects of sustained-release bupropion and supportive group therapy on cigarette consumption in patients with schizophrenia.

E Weiner1, M P Ball, A Summerfelt, J Gold, R W Buchanan.   

Abstract

OBJECTIVE: The study examined the efficacy, tolerability, and safety of supportive group psychotherapy and adjunctive sustained-release bupropion for nicotine addiction in patients with schizophrenia.
METHOD: Eight patients participated in a 14-week open-label trial. End expired breath carbon monoxide level, symptom levels, neuropsychological performance, and suppression of the P50 event-related potential were measured before and after the 14-week trial.
RESULTS: Patients showed a decrease in carbon monoxide levels that was not associated with any worsening in symptom, neuropsychological, or P50 suppression measures.
CONCLUSIONS: Use of sustained-release bupropion in combination with supportive group therapy may help patients with schizophrenia decrease their cigarette consumption.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11282701     DOI: 10.1176/appi.ajp.158.4.635

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  31 in total

1.  Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level.

Authors:  Marc De Hert; Dan Cohen; Julio Bobes; Marcelo Cetkovich-Bakmas; Stefan Leucht; David M Ndetei; John W Newcomer; Richard Uwakwe; Itsuo Asai; Hans-Jurgen Möller; Shiv Gautam; Johan Detraux; Christoph U Correll
Journal:  World Psychiatry       Date:  2011-06       Impact factor: 49.548

Review 2.  The feasibility of smoking reduction: an update.

Authors:  John R Hughes; Matthew J Carpenter
Journal:  Addiction       Date:  2005-08       Impact factor: 6.526

Review 3.  Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism?

Authors:  Robert M Roth; Mary F Brunette; Alan I Green
Journal:  Curr Psychiatry Rep       Date:  2005-08       Impact factor: 5.285

Review 4.  Pharmacotherapy for schizophrenia and co-occurring substance use disorders.

Authors:  Alan I Green
Journal:  Neurotox Res       Date:  2007-01       Impact factor: 3.911

5.  Smoking cessation in patients with psychiatric disorders.

Authors:  Alan J Gelenberg; Jose de Leon; A Eden Evins; Joseph J Parks; Nancy A Rigotti
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

6.  Interventions for the metabolic syndrome in schizophrenia: a review.

Authors:  Evangelos Papanastasiou
Journal:  Ther Adv Endocrinol Metab       Date:  2012-10       Impact factor: 3.565

Review 7.  Benefits and risks of pharmacological smoking cessation therapies in chronic obstructive pulmonary disease.

Authors:  Edwin J Wagena; Maurice P A Zeegers; Constant P van Schayck; Emiel F M Wouters
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

Review 8.  Interventions for smoking cessation and reduction in individuals with schizophrenia.

Authors:  Daniel T Tsoi; Mamta Porwal; Angela C Webster
Journal:  Cochrane Database Syst Rev       Date:  2013-02-28

9.  Prefrontal cognitive dysfunction is associated with tobacco dependence treatment failure in smokers with schizophrenia.

Authors:  Taryn G Moss; Kristi A Sacco; Taryn M Allen; Andrea H Weinberger; Jennifer C Vessicchio; Tony P George
Journal:  Drug Alcohol Depend       Date:  2009-05-17       Impact factor: 4.492

Review 10.  Clinical efficacy of bupropion in the management of smoking cessation.

Authors:  Douglas Jorenby
Journal:  Drugs       Date:  2002       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.